| Size | Price | |
|---|---|---|
| 1g | ||
| Other Sizes |
| Targets |
VHL
|
|---|---|
| ln Vitro |
In LNCaP and VCaP cells, ARD-266 (Compound 11; 100 nM; 1–24 hours) treatment efficiently lowers the level of AR protein in 3 hours and, with a 6-hour treatment, achieves almost total AR elimination[1]. Treatment with ARD-266 (Compound 11; 1–10,000 nM; 24 hours; LNCaP cells) can significantly reduce the mRNA levels of PSA, TMPRSS2, and FKBP5 genes by more than 50% at 10 nM in the LNCaP cell line[1]. It also effectively suppresses the expression of these genes in a dose-dependent manner.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: LNCaP and VCaP cells Tested Concentrations: 100 nM Incubation Duration: 1 hour, 3 hrs (hours), 6 hrs (hours), 12 hrs (hours), 24 hrs (hours) Experimental Results: Effectively diminished the AR protein level within 3 h and achieved near-complete AR elimination with a 6 h treatment in the LNCaP cells. RT-PCR[1] Cell Types: LNCaP cells Tested Concentrations: 1 nM, 10 nM, 100 nM , 1000 nM, 10000 nM Incubation Duration: 24 hrs (hours) Experimental Results: Effectively suppressed the expression of PSA, TMPRSS2, and FKBP5 genes in a dose-dependent manner and was capable of reducing the mRNA levels of PSA, TMPRSS2, and FKBP5 genes by >50 % at 10 nM in the LNCaP cell line. |
| References |
| Molecular Formula |
C52H59CLN6O7
|
|---|---|
| Molecular Weight |
915.513872385025
|
| Exact Mass |
914.413
|
| CAS # |
2666951-70-6
|
| PubChem CID |
145996519
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
66
|
| Complexity |
1830
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=NOC(=C1)[C@@H](C(C)C)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@H](CC(=O)N3CCC(CC3)C#CC4=CC=C(C=C4)C(=O)NC5C(C(C5(C)C)OC6=CC(=C(C=C6)C#N)Cl)(C)C)C7=CC=CC=C7)O
|
| InChi Key |
RTNONCBKGZNCJS-WPVVNVAYSA-N
|
| InChi Code |
InChI=1S/C52H59ClN6O7/c1-31(2)45(43-25-32(3)57-66-43)48(64)59-30-38(60)26-42(59)47(63)55-41(35-11-9-8-10-12-35)28-44(61)58-23-21-34(22-24-58)14-13-33-15-17-36(18-16-33)46(62)56-49-51(4,5)50(52(49,6)7)65-39-20-19-37(29-54)40(53)27-39/h8-12,15-20,25,27,31,34,38,41-42,45,49-50,60H,21-24,26,28,30H2,1-7H3,(H,55,63)(H,56,62)/t38-,41+,42+,45-,49?,50?/m1/s1
|
| Chemical Name |
(2S,4R)-N-[(1S)-3-[4-[2-[4-[[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]phenyl]ethynyl]piperidin-1-yl]-3-oxo-1-phenylpropyl]-4-hydroxy-1-[(2R)-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (109.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (5.46 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (5.46 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (5.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0923 mL | 5.4614 mL | 10.9229 mL | |
| 5 mM | 0.2185 mL | 1.0923 mL | 2.1846 mL | |
| 10 mM | 0.1092 mL | 0.5461 mL | 1.0923 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
